We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fulton Financial Rewards Shareholders: Is it Worth a Look?
Read MoreHide Full Article
Fulton Financial Corporation’s (FULT - Free Report) board of directors has announced a special cash dividend of 4 cents per share. The dividend will be paid on Dec 16, to shareholders on record as of Dec 4.
The company began paying special dividends from 2014. It started with a payment of 2 cents per share and thereafter, hiked the amount to 3 cents per share in 2017. Further, in 2018, Fulton Financial increased its special dividend to 4 cents per share.
Apart from special dividends, Fulton Financial consistently pays quarterly cash dividends. Since 2011, the company has been increasing its quarterly dividend on a regular basis. The most recent hike of 8.3% to 13 cents per share was announced in March 2019.
Besides Fulton Financial, there are several other financial institutions that have efficient capital-deployment plans in place. Some of these including United Bankshares, Inc. (UBSI - Free Report) , Bank OZK (OZK - Free Report) and Eaton Vance Corporation (EV - Free Report) have recently hiked their quarterly dividends.
Moreover, Fulton Financial has a share-repurchase plan in place. In October 2019, the company authorized $100 million worth share-buyback plan, expiring on Dec 31, 2020. Prior to this, the company had authorized share buyback worth $100 million in March that was completed in October.
Shares of Fulton Financial have rallied 5.5% over the past six months, outperforming the industry’s growth of 5.4%.
Fulton Financial’s earnings have witnessed 11.1% growth over the past three to five years. This uptrend is anticipated to continue as the company’s earnings will likely be up 19.5% in 2019.
Organic growth remains a key strength for Fulton Financial. The top line witnessed a five-year CAGR of 5.7% (2014-2018). Also, its projected sales growth rate of 9.6% for 2019 indicates continuation of the momentum.
Fulton Financial’s debt/equity ratio of 0.31 is lower than its industry’s average of 0.40. This reflects the company’s financial stability amid adverse economic situations.
Moreover, the stock looks undervalued, with respect to its price/earnings (P/E) (F1) and price/sales (P/S) ratios. It has a P/E (F1) ratio of 12.21, which is below the industry average of 12.63. Also, its P/S ratio of 2.74 is lower than the industry average of 2.88.
However, mounting non-interest expenses are concerns. Over the last five years (ended 2018), expenses witnessed a CAGR of 4.4%. This trend continued during the first nine months of 2019 as well. As the company grows inorganically and invests in banking franchise, expenses are likely to remain on the higher side.
Although the company’s net interest margin expanded in the first three quarters of 2019, the same is expected to be under pressure due to a low interest-rate environment. This is expected to impede net interest income growth.
Conclusion
Based on the above-mentioned factors, Fulton Financial seems to have promising prospects. However, one must keep an eye on concerns related to lower interest rates and elevated expense levels.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Fulton Financial Rewards Shareholders: Is it Worth a Look?
Fulton Financial Corporation’s (FULT - Free Report) board of directors has announced a special cash dividend of 4 cents per share. The dividend will be paid on Dec 16, to shareholders on record as of Dec 4.
The company began paying special dividends from 2014. It started with a payment of 2 cents per share and thereafter, hiked the amount to 3 cents per share in 2017. Further, in 2018, Fulton Financial increased its special dividend to 4 cents per share.
Apart from special dividends, Fulton Financial consistently pays quarterly cash dividends. Since 2011, the company has been increasing its quarterly dividend on a regular basis. The most recent hike of 8.3% to 13 cents per share was announced in March 2019.
Besides Fulton Financial, there are several other financial institutions that have efficient capital-deployment plans in place. Some of these including United Bankshares, Inc. (UBSI - Free Report) , Bank OZK (OZK - Free Report) and Eaton Vance Corporation (EV - Free Report) have recently hiked their quarterly dividends.
Moreover, Fulton Financial has a share-repurchase plan in place. In October 2019, the company authorized $100 million worth share-buyback plan, expiring on Dec 31, 2020. Prior to this, the company had authorized share buyback worth $100 million in March that was completed in October.
Shares of Fulton Financial have rallied 5.5% over the past six months, outperforming the industry’s growth of 5.4%.
So, is the stock worth considering to earn this special dividend? For this, we need to dig a bit deeper, and look at this Zacks Rank #3 (Hold) stock’s fundamentals and growth prospects. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Fulton Financial’s earnings have witnessed 11.1% growth over the past three to five years. This uptrend is anticipated to continue as the company’s earnings will likely be up 19.5% in 2019.
Organic growth remains a key strength for Fulton Financial. The top line witnessed a five-year CAGR of 5.7% (2014-2018). Also, its projected sales growth rate of 9.6% for 2019 indicates continuation of the momentum.
Fulton Financial’s debt/equity ratio of 0.31 is lower than its industry’s average of 0.40. This reflects the company’s financial stability amid adverse economic situations.
Moreover, the stock looks undervalued, with respect to its price/earnings (P/E) (F1) and price/sales (P/S) ratios. It has a P/E (F1) ratio of 12.21, which is below the industry average of 12.63. Also, its P/S ratio of 2.74 is lower than the industry average of 2.88.
However, mounting non-interest expenses are concerns. Over the last five years (ended 2018), expenses witnessed a CAGR of 4.4%. This trend continued during the first nine months of 2019 as well. As the company grows inorganically and invests in banking franchise, expenses are likely to remain on the higher side.
Although the company’s net interest margin expanded in the first three quarters of 2019, the same is expected to be under pressure due to a low interest-rate environment. This is expected to impede net interest income growth.
Conclusion
Based on the above-mentioned factors, Fulton Financial seems to have promising prospects. However, one must keep an eye on concerns related to lower interest rates and elevated expense levels.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>